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82 The Journal of Thoracic and Cardiobjective: Venoarterial extracorporeal membrane oxygenation is an establis
reatment option in patients with cardiogenic shock. This report reviews our 
xperience with this support system with respect to early and midterm outco
ell as predictors of survival.
ethods: From January 2003 until November 2006, 45 (0.8%) of 5750 pa
ndergoing cardiac surgery procedures required the following: temporary extra
oreal membrane oxygenation support coronary artery bypass grafting, n  20;
mplantation of a left ventricular assist device, n  5; heart transplantation, n  1;
eart and lung transplantation, n  1; coronary artery bypass grafting plus repai
ostinfarction ventricular septal defect, n  3; coronary artery bypass grafting p
itral valve repair, n  5; aortic valve replacement, n  2; coronary artery bypas
rafting plus aortic valve replacement, n  3; and other procedures, n  5.
xtracorporeal membrane oxygenation implantation was performed through 
emoral vessels or axillary artery or through the right atrium and ascending
dditional intra-aortic balloon pumps were used in 30 patients.
esults: Average patient age was 60.1  13.6 years. There were 35 male patie
verage duration of extracorporeal membrane oxygenation was 6.4  .5 days. Twen
y-five patients could be successfully weaned from extracorporeal membrane ox
tion. The 30-day mortality was 53% (24/45 patients). The in-hospital mortalit
1% (32/45 patients). Thirteen (29%) patients could be successfully discharged. A
ollow-up period of up to 3 years, 10 (22%) patients were still alive.
onclusions: Extracorporeal membrane oxygenation offers sufficient cardiopulm
ary support in adults with similar hospital and midterm survival rates to th
ther mechanical support systems. Early indication, alternative peripheral cann
ion techniques, and reduced anticoagulation to avoid perioperative bleeding c
mprove our results with increasing experience.
ince the first implantation by Hill and colleagues,1 xtracorporeal membrane
oxygenation (ECMO) has been an established treatment option in 
patients with refractory cardiogenic shock,2 providing prolonged but tempoary cardiac and respiratory support. Refractory myocardial dysfunction before or
vascular Surgery ● February 2008
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Puring cardiac surgical procedures with development 
evere cardiogenic shock is a rare but serious complica
ccompanied by an almost 100% mortality. In this s
roup of patients, ECMO might provide sufficient hemo
amic support to allow recovery from reversible myocar
njury.3,4
Many studies have reported excellent results of EC
n children,5 with outcome depending on the indication 
CMO. In adults, ECMO was reported to be less succe
ut early use demonstrated favorable results compared w
econdary implantation.6,7 Since 2002, we have us
CMO in our institution for patients who otherwise c
ot be weaned from extracorporeal circulation. The purp
f this study was to retrospectively review the early
idterm outcome of our patients and determine spec
redictors of survival.
aterials and Methods
rom January 2003 through November 2006, 45 of 5750 pa
ith refractory cardiogenic shock were placed on venoarte
CMO by using heparin-coated circuits (Medtronic, Minneapo
inn). The criterion to use ECMO for cardiopulmonary sup
as the inability to treat cardiogenic shock with conventi
ethods of support, such as catecholamines or an intra-a
alloon pump (IABP). The following cardiac surgical proced
ere performed: coronary artery bypass grafting (CABG) for a
yocardial infarction and preoperative cardiogenic shock, n  20;
mplantation of a left ventricular assist device, n  5; heart
ransplantation, n  1, heart and lung transplantation, n  1;
ABG plus repair of postinfarction ventricular septal defect, 
; CABG plus mitral valve repair, n  5; aortic valve replacemen
AVR), n  2; CABG plus AVR, n  3; and other procedures, 
 5.
CMO Circuit
he ECMO circuit consisted of a closed, heparin surface-co
ircuit of polyvinyl chloride tubing (Medtronic) and either a 
edicus Biopump (Medtronic) or a Jostra-Maquet Rotaflow RF
Jostra Medizintechnik, Hirrlingen, Germany), a centrifugal pu
hat propels blood through a hollow-fiber membrane oxygen
Maxima P.R.F., Medtronic). Blood flow was monitored by u
 Doppler flow probe placed on the arterial side of the c
enoarterial ECMO was instituted by means of peripheral ca
ation (common femoral artery and vein) in 29 (64%) pat
ubclavian artery and femoral vein cannulation in 8 (18%) pat
nd central cannulation (ascending aorta and right atrium) 
18%) patients. Central cannulation was performed in patie
ainly in the early course of our experience. For better p
Abbreviations and Acronyms
CABG coronary artery bypass grafting
ECMO extracorporeal membrane oxygenation
IABP  intra-aortic balloon pumpobilization and avoidance of bleeding, possible thrombus forma- E
The Journal of Thoracic,
t.
t
ion at the arterial cannula, and infective complications in
resence of an open sternotomy we changed our strategy
witched to a femoral or subclavian cannulation. In 2 patien
eceiving CABG and 1 receiving CABG plus mitral valve re
etrograde femoral artery cannulation was converted to subclav
rtery cannulation to achieve adequate ECMO support in rega
erforming better upper body oxygen saturation.
To avoid limb ischemia observed in some early cases 
eripheral cannulation, we optimized the distal limb perfusion
sing an 8-mm Dacron T-graft (end-to-side anastomosis to
emoral or subclavian artery), which was tied on a 20F a
annula (Medtronic) to ascertain both central arterial blood 
nd distal limb perfusion.
Initially, patients were heparinized as early as possible
chieve an activated clotting time of 160 to 180 seconds
ecause we observed too many cases of diffuse bleeding co
ations, we began to antagonize heparin completely and main
ufficient hemostasis to prevent further bleeding complicatio
nticoagulation with heparin was started after chest drainage 
ess than 50 mL/h. The target partial thromboplastin time 
etween 50 and 60 seconds.
ultidisciplinary Management Strategy
ll but 2 patients were supported with the intention to wean
CMO (bridge to recovery). Intravenous inotropic doses w
inimized or withdrawn to decrease myocardial oxygen dem
nd facilitate myocardial recovery, especially in patients w
cute myocardial infarctions. IABP support was encouraged w
atients received ECMO and was used in 30 of 45 patients. 
eptostomy or ventricular venting was not used. Recovery 
ssessed daily by means of clinical, hemodynamic, and echo
iographic findings.
When recovery was unlikely, patients were evaluated for tr
lantation or permanent assist implantation. Candidacy for tr
lantation or left ventricular assist device implantation was m
n a case-by-case basis. In all patients demonstrating recov
eaning was performed, with slow reduction of ECMO flow 
8 hours. ECMO had to be withdrawn from some patients, wi
nowledge that survival was unlikely and continued support was
utile.
Pump flows were chosen to supply at least adequate total
ystemic circulatory support (2.5 L · min1 · m2) and to
chieve a mixed venous oxygen saturation of more than 70%.
xygen flow was gradually adjusted as necessary to meet the
xygen requirements of the patient. Pulmonary artery pressure and
ardiac output were continuously monitored with a Swan–Ganz
atheter. Transesophageal echocardiography was performed mul-
iple times in all patients while receiving ECMO to enable pro-
ressive assessment of myocardial recovery and provide useful
nformation regarding myocardial contractility and ventricular fill-
ng during the weaning process.
eneral Patient Care
n all patients, sedation was morphine and midazolam based and
as used to achieve patient comfort while enabling a daily neu-
ologic assessment. Mechanical ventilation with biphasic positive
irway pressure was continued throughout the ECMO period.
CMO was set at a tidal volume of 5 to 7 mL/kg, a rate of 8
and Cardiovascular Surgery ● Volume 135, Number 2 383
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3
CSPreaths/min, a positive end-expiratory pressure of 10 cm H2O to
revent alveolar collapse, and a maximum ventilation pressur
0 cm H2O to avoid barotrauma. PCO2 was kept within the norm
ange to prevent organ damage. Respirator settings were ke
arameters known to avoid additional lung injury to avoid d
pment of pulmonary failure. Prone positioning was also u
CMO flow was never reduced to less than 1 L/min until e
ation to avoid any intrasystemic clotting. Enteral feeding 
nstituted in all patients on the first postoperative day and c
ed if tolerated.8 Antibiotics were used if infection was clinica
uspected. Hyperglycemia was avoided by means of continu
nfusion of insulin. Perfusion of the lower limbs was che
very 6 hours by means of physical examination, and 12
reatine kinase measurements were taken. All surviving pati
ere followed up after hospital discharge every 6 months i
utpatient department or by telephone to assess their clinical s
nd exercise capacity (100% complete follow-up).
ata Collection
ata collection was performed prospectively and focused on
raoperative and postoperative data, cannulation methods, durat
f support, blood product use, use of hemofiltration, and u
ABP. Data were also obtained for 30-day mortality and in
ital outcome.
BLE 2. Intraoperative data
Total CABG AVR CABG  MV
. 45 20 2 5
P 30 (67%) 15 (75%) 1 (50%) 4 (80%)
operation 5 (11%) 1 (5%) 1 (50%) 1 (20%)
B time (min) 156.6 66.1 131.8  66.4 23.5  3.1 193.8 71
BG, Coronary artery bypass grafting; AVR, aortic valve replacement;MVR, m
ect; HTX, heart transplantation; IABP, intra-aortic balloon pump; CPB, c
ABLE 1. Preoperative patient characteristics
Total CABG AVR CABG  M
o. 45 20 2 5
ge (y) 60.1  13.6 60.5  13 68.5 7.8 65.8 5
ale sex 35 (78%) 15 (75%) 1 (50%) 4 (80%
emale sex 10 (22%) 5 (25%) 1 (50%) 1 (20%
ody mass index 26.7 4.1 28.5  4 23.5 3.1 27.0 2
iabetes 38 (84%) 19 (95%) 1 (50%) 4 (80%
HT 37 (82%) 15 (75%) 2 (100%) 4 (80%
HT 17 (38%) 9 (45%) 1 (50%) 1 (20%
yperlipidemia 31 (69%) 17 (85%) 0 (0%) 2 (40%
VEF (%) 25.8  10 24.6  8.8 68.5 7.8 27.0 6
cute MI 32 (71%) 17 (85%) 0 (0%) 5 (100%
PR (preoperative) 31 (69%) 12 (60%) 1 (50%) 2 (40%
ABG, Coronary artery bypass grafting; AVR, aortic valve replacement;MVR
efect; HTX, heart transplantation; PHT, pulmonary hypertension; aHT, a
nfarction; CPR, cardiopulmonary resuscitation. *Including double-valve re
1).splantation (n  2), and type A aortic dissection (n  1).
84 The Journal of Thoracic and Cardiovascular Surgery ● Febr-
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tatistical Analysis
ll statistical analyses were performed with the Statview prog
Cary, NC). Categorical variables are expressed as percentages
ere evaluated with 2 or Fisher exact tests. Continuous variab
re expressed as means  standard deviation and were evaluat
y using the Student t test or the Kruskal–Wallis test. Logistic
egression analysis was used to determine the predictors of sur-
ival. Long-term survival was calculated according to the Kaplan-
eier method.
esults
emographics and pre-ECMO risk profiles of the 45 pa-
ients are summarized in Table 1. The patients were div
nto subgroups with relation to their indication for cardiac
urgery.
Table 2 demonstrates the intraoperative data of the 
erent ECMO groups. The support system was used in the
perating room in 30 (67%) patients and in the intensive
are unit in 15 (33%) patients. ECMO implantation was
uccessful in all cases.
Table 3 shows the outcome of ECMO support for
ifferent groups. Mean duration of ECMO support was 6.4
ABG  AVR LVAD CABG  VSD HTX Others*
3 5 3 2 5
2 (67%) 2 (40%) 3 (100%) 2 (100%) 1 (20%)
0 (0%) 0 (0%) 1 (33%) 1 (50%) 0 (0%)
62.3 52.6 144.3 14.4 173.0 46.0 224 80 315 66.4
valve repair; LVAD, left ventricular assist device; VSD, ventricular septal
ulmonary bypass. *Including double-valve replacement (n  2), liver
CABG  AVR LVAD CABG  VSD HTX Others*
3 5 3 2 5
51.0 18.0 57.0  16.0 69.3  1.5 45  18.4 54.0  18.4
3 (100%) 4 (80%) 3 (100%) 1 (50%) 4 (80%)
0 (0%) 1 (20%) 0 (0%) 1 (50%) 1 (20%)
23.5 7.1 23.9  3.5 26.4  2.8 22.8  2.2 26.0  2.2
1 (33%) 4 (80%) 3 (100%) 2 (100%) 4 (80%)
1 (33%) 5 (100%) 3 (100%) 2 (100%) 5 (100%)
1 (33%) 3 (60%) 2 (67%) 1 (50%) 1 (20%)
1 (33%) 3 (60%) 3 (100%) 1 (50%) 3 (60%)
21.7 2.9 18.0  2.7 23.3  2.9 22.6  5.0 35.0  7.0
3 (100%) 2 (40%) 3 (100%) 0 (0% ) 2 (40%)
3 (100%) 4 (80%) 3 (100%) 1 (50%) 5 (100%)
al valve repair; LVAD, left ventricular assist device; VSD, ventricular septal
l hypertension; LVEF, Left ventricular ejection fraction; MI, myocardial
ment (n  2), liver transplantation (n  2), and type A aortic dissection (nA
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P4.5 days; 25 (55%) patients were successfully weaned. Of
he 25 patients with successful weaning from ECMO, 13
52%) could be discharged from the hospital. IABP was
sed in 67% (30/45) of all patients and in 94% of the
atients with acute myocardial infarctions.
Five patients were assessed to be suitable candidates for
mplantation of a long-term ventricular assist device. All of
hese patients received the Heart Mate II left ventricular assist
evice (Thoratec, Inc, Woburn, Mass). Two patients died in
his group of multiorgan failure after successful weaning from
CMO. The remaining 3 patients could be discharged from the
ospital. One patient was suitable for heart and 1 patient for
TABLE 3. ECMO results
Total CABG AVR CA
No. 45 20 2
Duration of ECMO (d) 6.4 4.5 6.8 4.2 6.0 2.8
Successful weaning 25 (56%) 12 (60%) 2 (100%)
Bridge to long-term
assist device
5 (11%) 0 (0%) 0 (0%)
Heart transplantation 2 (4%) 0 (0%) 0 (0%)
Mechanical
ventilation (d)
12.6 10.3 11.6 8.8 11.0 1.4 1
ICU stay (d) 21.55 20.8 21.1 18.4 47.5 3.5 1
Post-ECMO hospital
stay (d)
25.6 19.2 18.2 15.8 30.5 14.8 3
30-d Mortality 24 (53%) 10 (50%) 1 (50%)
Discharged from
hospital
13 (67%) 6 (30%) 1 (50%)
In-hospital mortality 32 (71%) 14 (70%) 1 (50%)
CABG, Coronary artery bypass grafting; AVR, aortic valve replacement;M
defect; HTX, heart transplantation; ECMO, extracorporeal membrane ox
liver transplantation (n  2), and type A aortic dissection (n  1).
TABLE 4. Postoperative complications
Total CABG AVR CAB
No. 45 20 2
Rethoracotomy 39 (87%) 18 (90%) 2 (100%) 4
RBC transfusion 16.3 13.0 14.7 10.0 15.5 0.7 10
Infection 26 (58%) 10 (50%) 1 (50%) 2
Neurologic
complication
4 (9%) 1 (5%) 1 (50%) 1
Ischemia of lower
limbs
3 (7%) 2 (10%) 0 (0%) 0
Fasciotomy 6 (13%) 2 (10%) 0 (0%) 0
Renal Failure 39 (87%) 17 (85%) 2 (100%) 4
CVVHD 39 (87%) 17 (85%) 2 (100%) 4
Change of oxygenator 4 (9%) 1 (5%) 1 (50%) 0
ARDS 4 (9%) 1 (5%) 0 (0%) 0
Leg amputation 1 (2%) 0 (0%) 0 (0%) 0
CABG, Coronary artery bypass grafting; AVR, aortic valve replacement;M
defect; HTX, heart transplantation; RBC, red blood cell; CVVHD, continuou
double-valve replacement (n  2), liver transplantation (n  2), and type A a
The Journal of Thoraciconcomitant heart–lung transplantation. The patient undergo-
ng heart–lung transplantation died in the intensive care unit of
ultiorgan failure, and the patient undergoing heart transplan-
ation could be discharged.
In our early cases with ECMO, we observed a high inci-
ence of bleeding complications. Therefore, we have changed
ur anticoagulation regimen. Systemic heparinization was not
nitiated until chest drainage reduced to less than 50 mL/h. The
arget partial thromboplastin time to be attained was between
0 and 60 seconds.
Limb ischemia was observed in 3 of the early patients in
hom direct peripheral cannulation had been performed. As
MVR CABG  AVR LVAD CABG  VSD HTX Others
3 5 3 2 5
2.5 5.2 7.8 8.0  4.2 4.3  2.9 6.2  5.3 7.2  5.
0%) 2 (67%) 5 (100%) 2 (67%) 1 (50%) 0 (0%)
%) 0 (0%) 5 (100%) 0 (0%) 0 (0%) 0 (50%
%) 0 (0%) 0 (0%) 0 (0%) 2 (100%) 0 (50%
22.7 7.2 8.6 24.0 14.2 12.0  6.9 11.5  4.2 9.8  6.
23.4 21.0 28.5 24.0 14.2 45.3  1.4 54.5  4.5 8.8  6.
2.9 34.5 13.4 34.0  1.7 59.5  2.1 59.3  30.3 0.3  0.
0%) 3 (100%) 2 (40%) 1 (33%) 1 (50%) 2 (40%
%) 0 (0%) 3 (60%) 2 (67%) 1 (50%) 0 (0%)
00%) 3 (100%) 2 (40%) 1 (33%) 1 (50%) 5 (100%
itral valve repair; LVAD, left ventricular assist device; VSD, ventricular sep
tion; ICU, intensive care unit. *Including double-valve replacement (n 
MVR CABG  AVR LVAD CABG  VSD HTX Others*
3 5 3 2 5
) 3 (100%) 5 (100%) 3 (100%) 2 (100%) 2 (40%)
6.9 11.0 7 25.3  4.2 20.3 4.9 32.4 5.3 22.5  28
) 1 (33%) 4 (80%) 2 (67%) 2 (100%) 4 (80%)
) 0 (0%) 1 (20%) 0 (0%) 0 (0%) 0 (0%)
) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (20%)
) 0 (0%) 1 (20%) 1 (33%) 1 (50%) 1 (20%)
) 1 (33%) 5 (100%) 3 (100%) 2 (100%) 5 (100%
) 1 (33%) 5 (100%) 3 (100%) 2 (100%) 5 (100%
) 0 (0%) 0 (0%) 0 (0%) 1 (50%) 1 (20%)
) 0 (0%) 1 (20%) 0 (0%) 0 (0%) 2 (40%)
) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (20%)
itral valve repair; LVAD, left ventricular assist device; VSD, ventricular sep
ovenous hemodialysis; ARDS, adult respiratory distress syndrome. *IncludiBG  *
5
4.3  2
1 (2
0 (0 )
0 (0 )
6.7 2
7.0 3
3.2 8
4 (8 )
0 (0
5 (1 )
VR, m tal
ygena 2),G 
5
(80%
.4  .1
(40%
(20%
(0%
(0%
(80% )
(80% )
(0%
(0%
(0%
VR, m tal
s ven ngortic dissection (n  1).
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CSP consequence, distal limb perfusion was optimized wit
-mm Dacron T-graft anastomosed end-to-side to the c
on femoral or subclavian artery to maintain both ce
rterial blood flow and distal limb perfusion.9 Fasciotomy of
he lower leg was required in 6 patients because of 
artment syndrome. The rate of systemic infection defi
s a positive blood culture was 58% (26/45). Four (8
atients had neurologic complications caused by cereb
emorrhage (n  3) and stroke (n  1). Renal failure wa
he most common complication and occurred in 39 (86
atients. All patients with renal failure required continu
enovenous hemofiltration. Rethoracotomy for bleeding 
amponade had to be performed in 39 (86.7%) pati
able 4 lists the overall complications of ECMO sup
here was no significant difference between the groups 
ifferent indications with regard to incidence of sep
eurologic complications, blood transfusions, rethor
otomy, or renal failure.
Lower initial serum lactate levels were observed in
ients who could be weaned from ECMO and coul
ischarged from the hospital. In patients who failed t
eaned from ECMO, increased serum lactate levels 
isted permanently. In the late postoperative course, pati
ith septic shock and end-stage multiorgan failure 
uently had treatment-resistant lactate acidosis. Maxim
ostoperative lactate levels of patients who died during
ostoperative course are shown in Table 5. There wa
ignificant difference between the groups.
In patients who could not be weaned from ECMO
ain cause of death was persistent heart failure without
mprovement in cardiac function (18/20 patients). In 6
ients the decision to implant an ECMO device was 
BLE 5. Postoperative peak lactate levels between sur-
ors and nonsurvivors up to 72 hours after ECMO initia-
n
Group 1 Group 2 Group 3 Group 4
. 25 20 13 12
tate levels (mg/dL) 148 89 168 56 139 34 156 40
O, Extracorporeal membrane oxygenation; group 1, patients who could
weaned from extracorporeal membrane oxygenation; group 2, patients
o could not be weaned from extracorporeal membrane oxygenation;
up 3, hospital survivor; group 4, hospital nonsurvivor.
BLE 6. Diagnosis-related in-hospital survival
n (%)
stcardiotomy syndrome 3/11 (27)
operative cardiogenic shock 6/23 (26)
dge to LVAD/HTX 3/5 (60)gD, Left ventricular assist device; HTX, heart transplantation.
86 The Journal of Thoracic and Cardiovascular Surgery ● Febr-
)
ostoperatively, 1 to 2 days after the initial oper
rocedure.
Twenty-five patients could be successfully weaned fr
CMO, but only 13 patients could be discharged from
ospital. Therefore 12 of 25 patients had late complica
ith muliorgan failure and subsequently died.
The main causes of mortality in patients after succe
eaning from ECMO were pulmonary infections and se
ith consecutive multiorgan failure. These complicatio
ccurred more frequently in patients with advanced age
omorbidities, such as pulmonary hypertension a
iabetes.
Independent predictors of hospital survival revealed
nivariate regression analysis were absence of pulmon
ypertension (P  .04), absence of diabetes (P  .011), and
se of IABP (P  .04).
Regarding underlying disease states, the best progno
as observed for patients who were planned for perma
ssist device implantation or transplantation (60%, Table
After a follow-up period of up to 3 years, all o
ischarged patients were reassessed (mean follow-up, 
ears). The total 3-year mortality was 78% (35/45); Fi
 shows the Kaplan–Meier curve of survival. The 10
iving patients reported cardiac symptoms of New York
eart Association class II (6 patients) or III (4 patients).
our of the 10 patients had a history of congestive heart
ailure with need for readmission; 1 patient was admitted
ecause of pneumonia, and 1 patient reported end-stage
enal failure requiring dialysis.
iscussion
espite permanent surgical and medical development, cardio-
igure 1. Kaplan–Meier survival curve of all patients with extra-
orporeal membrane oxygenation and the number of patients at
isk.A
iv
io
o
ac
CM
e
hA
o
re
rienic shock remains a major complication in cardiac surgery
uary 2008
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Procedures, especially when patients demonstrate heart fail
ymptoms or cardiogenic shock preoperatively.10 Although the
ajority of patients can be weaned from cardiopulmo
ypass with moderate inotropic drugs, IABP support, or 
p to 3% to 5% have severe persistent myoca
ysfunction.11
In this patient group ECMO might provide suffic
emodynamic and respiratory support to allow recov
rom myocardial injury and extend the decision time 
ridging therapy. Recent studies report in-hospital survi
ates with the use of ECMO ranging from 20% to 50%
ortality rates of 50% to 70%.12,13 In our study there was
igh 30-day mortality of 53%; in-hospital mortality 
1%, and 3-year mortality was 78%. Our survival ra
omparable with those of other study groups.3,14
Based on the experience in our institution, ECMO 
py is now considered to be a valuable option for trea
f myocardial infarction and low output syndrome in 
iac procedures in the operating room. We postulate 
atients with severe left ventricular dysfunction, sev
ardiomyopathy, primary perioperative respiratory failur
ostcardiotomy syndrome, and myocardial infarction mig
enefit more if they receive this treatment option during
peration or at least very early in the postoperative cou
revent clinical deterioration. Early use of circulatory s
ort might avoid additional myocardial damage caused
notropic medication or hypoxia and thus provides a t
ent option that allows for recovery from the myoca
njury over a prolonged period. Patients in periopera
hock or those after long cardiac procedures need a 
ormal cardiac output to recover. On the other hand
ients who use a bridge to permanent assist device im
ation or transplantation demonstrate the best outcome.
The use of IABP also was a predictor for better sur
ased on the hypothesis of additional pulsatile flow, re
ion of afterload, and better coronary flow, we now
ABP routinely in patients undergoing ECMO who do
emonstrate contraindications to IABP.13,14
In the early cases of ECMO, we observed frequent b
ng problems, especially when platelet inhibitors had b
dministered before surgical intervention. After changi
ur postoperative anticoagulation protocol, there was a
uction in bleeding complications, but still, most pati
ad to undergo reoperation at some point during the 
perative course.
Renal failure and need for hemofiltration was ano
requent complication in our study group. Of interest i
igh incidence of renal failure during the postopera
ourse of 9 patients, which occurred days after succe
eaning from ECMO. Perioperative high lactate concen
ions were observed in nonsurvivor patients; however, 
id not reach statistical significance.
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The duration of ECMO in our patient group was 6.4  4.5
ays and thus longer compared with those seen in other 
roups.3,13,14 Our strategy was to provide sufficient time
ecover from myocardial injury; however, the study does
rove any benefit from that difference in strategy. The 
ent duration should be decided individually, depending
eart and lung recovery. Improvement of our ECMO stra
o reduce system-related complications led us to extend
uration of ECMO to achieve maximal recovery.
The follow-up period was short but demonstrated 
nce successfully discharged from the hospital, patients 
n acceptable midterm survival with class II to III 
ailure and a low rate of readmission to the hospital. 
esults justify the use of ECMO, even if only slightly 
han 20% of the patients survived up to 3 years aft
ardiac operation.
In summary, current use of the heparin-precoated sys
nd improvements in patient management reduced the com-
lexity of ECMO. System-related complications are rare,
nd thus the threshold and timing for system implantation
hould be liberal. Therefore complex patients who currently
ight not be considered for ECMO could be able to benefit
rom ECMO in the future.
This article describes a retrospective analysis of our
linical experience with mixed indications for ECMO im-
lantation. Despite a variety of changes in the management
f our patients, we still had a relatively high rate of
ortality.
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